Henagliflozin Proline

脯氨酸恒格列净

Report date: 2026/03/30 17:02:26

Base Information

Drug NameHenagliflozin Proline
Drug Alias Name恒格列净Henagliflozin ProlineHenagliflozein Proline瑞沁️SHR-3824
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSodium/glucose cotransporter 2 inhibitors
TargetsSodium/glucose cotransporter 2
Therapy Area/IndicationsDiabetes Mellitus, Type 2Diabetes MellitusRenal Insufficiency +[6] 
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaDiabetes Mellitus, Type 2
Original Approved Country/TerritoryMainland China
Original Approved Date2021/12/31
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJiangsu Hengrui Medicine Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesFujian Medical University Union HospitalJiangsu Hengrui Medicine Co Ltd
Inactive CompaniesShandong Shengdi Pharmaceutical Co LtdShanghai Hengrui Pharmaceutical Co Ltd
Active IndicationsDiabetes Mellitus, Type 2Kidney DiseasesMetabolic Dysfunction-Associated Steatotic Liver Disease
Inactive IndicationsDiabetes MellitusRenal InsufficiencyHepatic Insufficiency

Other Information

ATC CodeA10BK
Related LinksN/A